Abstract:The clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) system, an RNA-guided nuclease for specific genome editing in vivo, has been adopted in a wide variety of organisms. In contrast, the in vitro application of the CRISPR/Cas9 system has rarely been reported. We present here a highly efficient in vitro CRISPR/Cas9-mediated editing (ICE) system that allows specific refactoring of biosynthetic gene clusters in Streptomyces bacteria and other large DNA fragments. Cleavage by Cas9 of circular pUC18 DNA was investigated here as a simple model, revealing that the 3'→5' exonuclease activity of Cas9 generates errors with 5 to 14 nucleotides (nt) randomly missing at the editing joint. T4 DNA polymerase was then used to repair the Cas9-generated sticky ends, giving substantial improvement in editing accuracy. Plasmid pYH285 and cosmid 10A3, harboring a complete biosynthetic gene cluster for the antibiotics RK-682 and holomycin, respectively, were subjected to the ICE system to delete the rkD and homE genes in frame. Specific insertion of the ampicillin resistance gene (bla) into pYH285 was also successfully performed. These results reveal the ICE system to be a rapid, seamless, and highly efficient way to edit DNA fragments, and a powerful new tool for investigating and engineering biosynthetic gene clusters. Importance: Recent improvements in cloning strategies for biosynthetic gene clusters promise rapid advances in understanding and exploiting natural products in the environment. For manipulation of such biosynthetic gene clusters to generate valuable bioactive compounds, efficient and specific gene editing of these large DNA fragments is required. In this study, a highly efficient in vitro DNA editing system has been established. When combined with end repair using T4 DNA polymerase, Cas9 precisely and seamlessly catalyzes targeted editing, including in-frame deletion or insertion of the gene(s) of interest. This in vitro CRISPR editing (ICE) system promises a step forward in our ability to engineer biosynthetic pathways.

Cas11 enables genome engineering in human cells with compact CRISPR-Cas3 systems

CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells

Programmed genome editing by a miniature CRISPR-Cas12f nuclease

Programmable DNA Repair with CRISPRa/i Enhanced Homology-Directed Repair Efficiency with a Single Cas9

Engineered minimal type I CRISPR-Cas system for transcriptional activation and base editing in human cells

Genome editing in mammalian cells using the CRISPR type I-D nuclease

Structure and genome editing of type I-B CRISPR-Cas

Exploiting activation and inactivation mechanisms in type I-C CRISPR-Cas3 for genome-editing applications

Improved genome editing by an engineered CRISPR-Cas12a

RNA-Guided Human Genome Engineering via Cas9

In Vitro CRISPR/Cas9 System for Efficient Targeted DNA Editing

High-Throughput Profiling of Cas12a Orthologues and Engineered Variants for Enhanced Genome Editing Activity

Multiplex Genome Engineering Using CRISPR/Cas Systems

Genome engineering using the CRISPR-Cas9 system

DNA targeting by compact Cas9d and its resurrected ancestor

Rationally designed Campylobacter jejuni Cas9 enables efficient gene activation and base editing

Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing

A transferrable and integrative type I-F Cascade for heterologous genome editing and transcription modulation

Cas12n nucleases, early evolutionary intermediates of type V CRISPR, comprise a distinct family of miniature genome editors

Bacterial genome editing by coupling Cre-lox and CRISPR-Cas9 systems

An engineered Cas12i nuclease that is an efficient genome editing tool in animals and plants